1.46 billion Swiss francs ($1.8 billion) is the all-cash figure South Korea's Samsung Biologics has placed on Switzerland's PolyPeptide Group. The offer was disclosed on Monday. Cash only: no equity component was attached to the bid.
Deal at a glance
| Item | Detail |
|---|---|
| Offer price | CHF 1.46 billion |
| Dollar equivalent | $1.8 billion |
| Structure | All-cash |
| Acquirer | Samsung Biologics (South Korea) |
| Target | PolyPeptide Group (Switzerland) |
| Announced | Monday |
The offer
CHF 1.46 billion converts to $1.8 billion. That is the full cash consideration Samsung Biologics has put on the table for PolyPeptide Group. No board recommendation from the Swiss company or closing timeline appeared in Monday's disclosure.